An Open Multicentre, Multicountry Study to Evaluate Long-term Antibody Persistence and Immune Memory Between Years 11 and 15 After the Primary Study HAB-084 in Which Healthy Adolescents Were Vaccinated With Twinrix™ Adult Following a Two-dose Schedule or Twinrix™ Junior Following a Three-dose Schedule.

Trial Profile

An Open Multicentre, Multicountry Study to Evaluate Long-term Antibody Persistence and Immune Memory Between Years 11 and 15 After the Primary Study HAB-084 in Which Healthy Adolescents Were Vaccinated With Twinrix™ Adult Following a Two-dose Schedule or Twinrix™ Junior Following a Three-dose Schedule.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Nov 2016

At a glance

  • Drugs Hepatitis A-hepatitis B vaccine (Primary)
  • Indications Hepatitis A; Hepatitis B
  • Focus Pharmacodynamics
  • Acronyms HAB-084-EXT
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
  • Most Recent Events

    • 19 Apr 2016 Results of long-term follow-up (n=162) published in the Vaccine
    • 14 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Jun 2012 Planned number of patients changed from 210 to 241 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top